Cytogenetic characterisation and proteomic profiling of the Imatinib-resistant cell line KCL22-R

International Journal of Oncology

Volumn 31, Issue 1, 2007, Pages 121-128

  Rosenhahn, Julia ^a   Weise, Anja ^a   Michel, Susanne ^a   Hennig, Katrin ^a   Hartmann, Isabell ^a   Schiefner, Jana ^a   Schubert, Katrin ^a   Liehr, Thomas ^a   Von Eggeling, Ferdinand ^a   Loncarevic, Ivan F ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

BCR ABL; Chronic myeloid leukemia; Imatinib; Initial resistance; Karyotype evolution; SELDI

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANEUPLOIDY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHROMOSOME 6; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; DRUG RESISTANCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; KARYOTYPING; METABOLISM; PROTEOMICS; TUMOR CELL LINE;

ANEUPLOIDY; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 6; CYTOGENETIC ANALYSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEINS; PROTEOMICS; PYRIMIDINES;

EID: 34548550341     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.1.121     Document Type: Article

References (37)

1. Rowley JD: Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290-293, 1973.
2. Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts VK, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T and Stone M: Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306: 277-280, 1983.
3. Lugo TG, Pendergast AM, Muller AJ and Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079-1082, 1990.
4. Deininger MWN, Goldman JM and Melo JV: The molecular biology of chronic myeloid leukemia. Blood 96: 3343-3356, 2000.
5. Melo JV, Hughes TP and Apperley JF: Chronic Myeloid Leukemia. Hematology: 132-152, 2003.
6. Deininger M, Buchdunger E and Druker BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640-2653, 2005.
7. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN and Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880, 2001.
8. Barthe C, Gharbi Mj, Lagarde V, Chollet C, Cony-Makhoul P, Reiffers J, Goldman JM, Melo JV and Mahon FX: Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571. Br J Haematol 119: 109-111, 2002.
9. Gambacorti-Passerini C, Gundry R, Piazza R, Galietta A, Rostagno R and Scapozza L: Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 4: 75-85, 2003.
10. Hochhaus A: Cytogenetic and molecular mechanisms of resistance to imatinib. Semin Hematol 40: 69-79, 2003.
11. Cortes J and O'Dwyer ME: Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am 18: 671-684, 2004. (Pubitemid 38969138)
12. Bacher U, Haferlach T, Hiddemann W, Schnittger S, Kern W and Schoch C: Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. Cancer Genet Cytogenet 157: 53-61, 2005.
13. Fabarius A, Giehl M, Frank O, Duesberg P, Hochhaus A, Hehlmann R and Seifarth W: Induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia 19: 1573-1578, 2005.
14. Tang N, Tornatore P and Weinberger SR: Current developments in SELDI affinity technology. Mass Spectrom Rev 23: 34-44, 2004.
15. Paradis V, Degos F, Dargere D, Pham N, Belghiti J, Degott C, Janeau JL, Bezeaud A, Delforge D, Cubizolles M, Laurendeau I and Bedossa P: Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 41: 40-47, 2005.
16. Li Y, Dang TA, Shen J, Perlaky L, Hicks J, Murray J, Meyer W, Chintagumpala M, Lau CC and Man TK: Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics 6: 3426-3435, 2006.
17. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E and Bhalla K: Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280: 26729-26734, 2005.
18. Melle C, Ernst G, Schimmel B, Bleul A, Mothes H, Kaufmann R, Settmacher U and von Eggeling F: Different expression of calgizzarin (S100A11) in normal colonic epithelium, adenoma and colorectal carcinoma. Int J Oncol 28: 195-200, 2006.
19. Cheung PK, Woolcock B, Adomat H, Sutcliffe M, Bainbridge TC, Jones EC, Webber D, Kinahan T, Sadar M, Gleave ME and Vielkind J: Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res 64: 5929-5933, 2004.
20. Melle C, Kaufmann R, Hommann M, Bleul A, Driesch D, Ernst G and von Eggeling F: Proteomic profiling in microdissected hepatocellular carcinoma tissue using ProteinChip technology. Int J Oncol 24: 885-891, 2004.
21. Melle C, Bogumil R, Ernst G, Schimmel B, Bleul A and von Eggeling F: Detection and identification of heat shock protein 10 as a biomarker in colorectal cancer by protein profiling. Proteomics 6: 2600-2608, 2006.
22. Escher N, Spies-Weisshart B, Kaatz M, Melle C, Bleul A, Driesch D, Wollina U and von Eggeling F: Identification of HNP3 as a tumour marker in CD4+ and CD4- lymphocytes of patients with cutaneous T-cell lymphoma. Eur J Cancer 42: 249-255, 2006.
23. Mahon FX, Deininger MWN, Schultheis B, Chabrol J, Reiffers J, Goldman JM and Melo JV: Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96: 1070-1079, 2000.
24. Verma R and Babu A: Human Chromosomes. Elsevier Science Ltd, 1989.
25. Weise A, Liehr T, Efferth T, Kuechler A and Gebhart E: Comparative M-FISH and CGH analyses in sensitive and drug-resistant human T-cell acute leukemia cell lines. Cytogenet Genome Res 98: 118-125, 2002.
26. Stentoft J, Pallisgaard N, Kjeldsen E, Holm MS, Nielsen JL and Hokland P: Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. Eur J Haematol 67: 302-308, 2001. (Pubitemid 34135443)
27. Liehr T, Heller A, Starke H, Rubtsov N, Trifonov V, Mrasek K, Weise A, Kuechler A and Claussen U: Microdissection based high resolution multicolor banding for all 24 human chromosomes. Int J Mol Med 9: 335-339, 2002.
28. Kriegova E, Melle C, Kolek V, Hutyrova B, Mrazek F, Bleul A, du Bois RM, von Eggeling F and Petrek M: Protein profiles of bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 173: 1145-1154, 2006.
29. Kubonishi I and Miyoshi I: Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. Int J Cell Cloning 1: 105-117, 1983.
30. Yuan ZM, Huang Y, Ishiko T, Nakada S, Utsugisawa T, Kharbanda S, Wang R, Sung P, Shinohara A, Weichselbaum R and Kufe D: Regulation of Rad51 function by c-Abl in response to DNA damage. J Biol Chem 273: 3799-3802, 1998. (Pubitemid 28103233)
31. Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA, Camphausen K and Tofilon PJ: Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 63: 7377-7383, 2003.
32. Johansson B, Fioretos T and Mitelman F: Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107: 76-94, 2002.
33. Tipping AJ, Deininger MW, Goldman JM and Melo JV: Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol 31: 1073-1080, 2003.
34. Desplat V, Belloc F, Lagarde V, Boyer C, Melo JV, Reiffers J, Praloran V and Mahon FX: Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines. Cancer 103: 102-110, 2005.
35. Raitano AB, Halpern JR, Hambuch TM and Sawyers CL: The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. PNAS 92: 11746-11750, 1995.
36. Ho FM, Liu SH, Liau CS, Huang PJ and Lin-Shiau SY: High glucose-induced apoptosis in human endothelial cells is mediated by sequential activations of c-Jun NH2-terminal kinase and caspase-3. Circulation 101: 2618-2624, 2000.
37. Trimarchi JM and Lees JA: Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 3: 11-20, 2002.